Mevalonate (lithium salt)

Mevalonate is an intermediate in the mevalonate pathway of cholesterol synthesis.¹ It inhibits cell death induced by the HMG-CoA reductase inhibitor simvastatin (Item Nos. 10010344 | 10010345) in C2C12 myoblasts when used at concentrations ranging from 80 to 110 µM.² Mevalonate (500 µM) reverses decreases in proliferation induced by the HMG-CoA reductase inhibitor lovastatin (Item No. 10010338) in several colon cancer cell lines, including RKO and SW480 cells.³ It increases lovastatin-induced decreases in the expression of the genes encoding Axin2, ectodermal-neural cortex 1 (ENC1), BCL2-like 1 (BCL2-L1), and cyclin D1 when used at a concentration of 500 µM. Mevalonate (50 µM) increases Rac1 protein levels, as well as increases Rac1 farnesylation induced by the arachidonic metabolite 15(S)-HETE (Item No. 34720) in human dermal microvascular endothelial cells (HDMVECs).⁴

WARNING This product is not for human or veterinary use.

1. Yazawa, H., Zimmermann, B., Asami, Y., et al. Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J. Periodontol. 76(2), 295-302 (2005).

2. Moschetti, A., Dagda, R.K., and Ryan, R.O. Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. Nanomedicine 37, 102439 (2021).

3. Gong, L., Xiao, Y., Xia, F., et al. The mevalonate coordinates energy input and cell proliferation. Cell Death Dis. 10(4), 327 (2019).

4. Singh, N.K., Kundumani-Sridharan, V., and Rao, G.N. 12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation. Blood 118(20), 5701-5712 (2011).